Skip to main content
  1. Right Decisions
  2. Back
  3. Breast pathways (referral pathways)
  4. Gynaecomastia
Announcements and latest updates

Welcome to the Right Decision Service (RDS) newsletter for August 2024.

  1. Contingency planning for RDS outages

Following the recent RDS outages, Tactuum and the RDS team have been reviewing the learning from these incidents. We are committed to doing all we can to ensure a positive outcome by strengthening the RDS to make it fully robust and clinically resilient for the future.

We would like to invite you to a webinar on 26th September 3-4 pm on national and local contingency planning for future RDS outages.  Tactuum and the RDS team will speak about our business continuity plans and the national contingency arrangements we are putting in place. This will also be a space to share local contingency plans, ideas and existing good practice. We would also like to gather your views on who we should send communications to in the event of future outages.

I have sent a meeting request for this date to all editors – please accept or decline to indicate attendance, and please forward on to relevant contacts. You can also contact Olivia.graham@nhs.scot directly to register your interest in participating.

 

2.National  IV fluid prescribing  calculator

This UK CA marked calculator is now live at https://righdecisions.scot.nhs.uk/ivfluids  . It has been developed by a multiprofessional steering group of leads in IV fluids management, as part of the wider Modernising Patient Pathways Programme within the Centre for Sustainable Delivery.  It aims to address a known cause of clinical error in hospital settings, and we hope it will be especially useful to the new junior doctors who started in August.

Please do spread the word about this new calculator and get in touch with any questions.

 

  1. New toolkits

The following toolkits are now live;

  1. Updated guidance on current and future Medical Device Regulations

We have updated and simplified this guidance within our standard operating procedures. We have clarified the guidance on how to determine whether an RDS tool is a medical device, and have provided an interactive powerpoint slideset to steer you through the process.

 

  1. Guide to six stages of RDS toolkit development

We have developed a guide to support editors and toolkit leads through the process of scoping, designing, delivering, quality assuring and implementing a new RDS toolkit.  We hope this will help in project planning and in building shared understanding of responsibilities throughout the full development process.  The guide emphasises that the project does not end with launch of the new toolkit. Implementation, communication and evaluation are ongoing activities throughout the lifetime of the toolkit.

 

  1. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:
  • Thursday 5 September 1-2 pm
  • Wednesday 24 September 4-5 pm
  • Friday 27 September 12-1 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

7 Evaluation projects

Dr Stephen Biggart from NHS Lothian has kindly shared with us the results of a recent survey of use of the Edinburgh Royal Infirmary of Edinburgh Anaesthesia toolkit. This shows that the majority of consultants are using it weekly or monthly, mainly to access clinical protocols, with a secondary purpose being education and training purposes. They tend to find information by navigating by specialty rather than keyword searching, and had some useful recommendations for future development, such as access to quick reference guidance.

We’d really appreciate you sharing any other local evaluations of RDS in this way – it all helps to build the evidence base for impact.

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

 

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

Gynaecomastia

Warning

The Gynaecomastia Pathway includes recommendations for management in primary care and in the breast unit.

Click the play button below to find out more about about breast lesions in men.

 

Background

The Symptomatic Breast Speciality Delivery Group was established to support and look at new innovative ways to delivering Symptomatic Breast services across NHS Scotland.

Through development of Once for Scotland approaches for delivery of care, focus is being placed on looking at opportunities to develop clinical pathways to reduce unwarranted variation in delivery of quality healthcare and to sustainably improve waiting times for non-urgent care within breast services.

Speciality Delivery Groups have been established to engage and fully utilise the role of clinical leadership across NHS Scotland.

Development of the Gynaecomastia Pathway has been progressed through the Symptomatic Breast Speciality Delivery Group.

The recommendations have not followed the standard process used by the Scottish Intercollegiate Guidelines Network (SIGN) but are based on available guidance and expert opinion, with peer review to provide quality assurance.

This guidance will be reviewed and updated as new evidence emerges.

 

Definition

Gynaecomastia is a benign enlargement of the male breast with firm tissue extending concentrically beyond the nipple. It may unilateral, bi-lateral, painful or asymptomatic4.

 

Consensus

A common theme during the Breast Speciality Delivery group meetings has focused on the referral of men with breast issues to secondary care services.

A consensus was formed around the principles that:

  1. Gynaecomastia is a breast manifestation of a systemic problem. Secondary care referral and investigation is not necessary in the vast majority of cases and variation in practice and over investigation are common.
  2. Breast lumps in men (rather than generalised swelling of the breast tissue) require specific investigation.

 

Pathway recommendations 1. Management in primary care

a.   Examination should distinguish between general swelling of the breast tissue or a specific lump. Swelling of breast tissue due to gynaecomastia is often asymmetrical. A soft, well-defined lump away from the breast tissue is likely to be a lipoma and may not require further investigation, especially if other lipomas are present. A specific lump within the breast tissue (rather than generalised breast swelling) or other features of concern (such as nipple inversion, nipple discharge or distortion) requires referral to the breast unit.

b.   A history should be taken for causes of gynaecomastia, including drugs (prescribed or otherwise), alcohol, protein supplements, liver disease, testicular issues and obesity (see Systemic conditions associated with gynaecomastia). In those going through puberty or the very old, gynaecomastia is likely to be due to normal, age-related hormonal changes. Drugs causing gynaecomastia include antioestrogens, spironolactone, calcium channel blockers, proton pump inhibitors, cimetidine, allopurinol, digoxin, opioids, anabolic steroids and cannabis. The use of protein supplements also appears to be associated. Testicular examination should be performed for atrophy, absence or lump. If any predisposing cause is identified this should be addressed. Gynaecomastia is likely to persist or recur after treatment if the underlying cause is still present. Pubertal gynaecomastia will usually resolve spontaneously but can take many months.

c.   In the absence of a predisposing cause, consider blood tests for urea and electrolytes, liver function tests, Luteinizing hormone, Follicle Stimulating Hormone testosterone, prolactin, beta human chorionic gonadotropin- and alpha-fetoprotein and thyroid function tests and address any abnormalities.

d.   Consider medical treatment for persisting pubertal gynaecomastia or where there is no obvious predisposing cause or abnormality of blood tests. This is an unlicensed indication. It is most useful for recent onset gynaecomastia and usually improves breast sensitivity. If prescription of a medication out with it's licensed indication is being considered discussion with secondary care colleagues is an option should this be felt necessary for the small number of patients who may benefit.

  • Tamoxifen 10mg once daily for 3-9 months
  • Anastrozole 1mg daily for 3 months

e.   Surgical excision for cosmesis is considered through the exceptional aesthetic referral pathway.

 

Pathway recommendations 2. Management in the breast unit

  1. Those with a breast lump (not just generalised breast swelling) should undergo triple assessment. Those with a clinically obvious lipoma may not need further investigation.
  2. Investigation and treatment pathways are otherwise as noted above for primary care.
  3. When an obvious cause of gynecomastia is present, further investigation is not necessary.
  4. Consider mammography in those over 40. Ultrasound scanning is not required unless a specific breast lump (not just generalised breast swelling or a lipoma) is present.

 

Systemic conditions associated with gynaecomastia

  • Testicular failure
  • Liver disease
  • Obesity
  • Renal failure
  • Adrenal disease
  • Hyperthyroidism
  • Testicular cancer
  • Lung cancer
  • Klinefelter’s syndrome

 

References

  1. Association of Breast Surgery (2021) Investigation and management of gynaecomastia in primary and secondary care Last accessed 22 August 2023
  2. Royal College or Radiologists (2019) Guidance on screening and symptomatic breast imaging, Fourth edition Last accessed 22 August 2023
  3. Thiruchelvam P, Churchill W, Walker JN, Rose K, Lewis J, Al-Mufti R. Gynaecomastia. BMJ 016;354:i4833 https://doi.org/10.1136/bmj.i4833
  4. Niewoehner, CB. Gynaecomastia. BMJ Best Practice. Oct 2022. https://bestpractice.bmj.com/topics/en-gb/869 Last accessed 22 August 2023

 

Editorial Information

Last reviewed: 09/08/2023

Next review date: 10/02/2025

Author(s): Symptomatic Breast Speciality Delivery Group.

Approved By: Centre for Sustainable Delivery